Showing 7241-7250 of 8691 results for "".
- Leading Scientist Behind SkinCeuticals Dies At 76https://practicaldermatology.com/news/20130712-dr_sheldon_pinnell_the_founding_father_of_topical_antioxidants_leading_scientist_behind_skinceuticals_and_chief_emeritus_of_the_division_of_dermatolog/2459500/Dr. Sheldon Pinnell, an internationally eminent scientist, dermatologist, leading scientist behind L'Oreal-owned SkinCeuticals, and J. Lamar Callaway Professor Emeritus of Dermatology and Chief Emeritus of the Division of Dermatology at Duke University, passed away peacefully in Durham, North Caroli
- Investigational Psoriasis Agent On Track for Regulatory Submission This Yearhttps://practicaldermatology.com/news/20130708-investigational_psoriasis_agent_on_track_for_regulatory_submission_this_year/2459501/Results from a Phase III trial showed that the experimental drug secukinumab (Novartis) showed superiority to etanercept (Enbrel, Amgen) at clearing skin in patients with moderate-to-severe plaque psoriasis. The FIXTURE trial, which randomized 1,307 patients with moderate-to-severe plaque psoriasis,
- Promising Data Presented for Viviscal Oral Supplement to Promote Hair Growthhttps://practicaldermatology.com/news/20130625-promising_data_presented_for_viviscal_oral_supplement_to_promote_hair_growth/2459510/An office-dispensed oral food supplement appears to promote existing hair growth for women suffering from temporary thinning hair, according to data presented at the World Hair Congress in Edinburgh, Scotland this spring. Subjects treated with Viviscal Hair Nourishment System
- Phase III Data Show Galderma's Topical Redness Reducer is Effective, Safehttps://practicaldermatology.com/news/20130625-phase_iii_data_show_galdermas_topical_redness_reducer_is_effective_safe/2459511/Topical brimonidine tartrate gel 0.5% is safe and effective for the management of erythema of rosacea, with benefit evidence as early as 30 minutes after application, new data show. (JDD, 12(6):650-656) Data from two identically designed randomized, double-blind, vehicle controlled phase III trials
- Steve Perry Undergoes Cancer Surgeryhttps://practicaldermatology.com/news/20130611-steve_perry_undergoes_cancer_surgery/2459515/Former Journey singer Steve Perry had a cancerous mole on his right cheek removed recently. Test results found it positive for melanoma. Perry had to undergo two procedures to rid his skin of all of the cancer cells, according to his physicians, and no further treatment will be necessary.
- Stelara Approved for Self-Administrationhttps://practicaldermatology.com/news/20130611-stelara_approved_for_self-administration/2459518/The FDA has approved Stelara (ustekinumab) for self-administration. Previously intended for subcutaneous administration under the supervision of a physician, Stelara can now be administered by patients at home. The drug is approved for the treatment of adult patients with moderate to severe plaque p
- Results of SB204 Clinical Study in Acne Releasedhttps://practicaldermatology.com/news/20130605-results_of_sb204_clinical_study_in_acne_released/2459523/Nitric oxide releasing drug candidate SB204 reduces colonization of the acne-causing bacteria Propionibacterium acnes (P. acnes) in the skin of healthy volunteers, according to a recent trial. This study, in combination with Novan Therapeutics' earlier findings regarding sebum production, suggests t
- Research Shows CLn BodyWash Effective for Children with Eczemahttps://practicaldermatology.com/news/20130603-research_shows_cln_bodywash_effective_for_children_with_eczema/2459524/Clinical study results show that TopMD Skin Care's CLn BodyWash helps ease the symptoms of eczema. The article, “A Novel Sodium Hypochlorite Cleanser Shows Clinical Response and Excellent Acceptability in the Treatment of Atopic Dermatitis,” details the results of 18 children ages 2 to 11 with moder
- Two Melanoma Drugs Win FDA Approvalhttps://practicaldermatology.com/news/20130530-two_melanoma_drugs_win_fda_approval/2459528/The FDA approved two new drugs for metastatic or inoperable melanoma, dabrafenib (Tafinlar) and trametinib (Mekinist). Dabrafenib is an inhibitor of the BRAF gene when it carries the so-called V600E mutation. Trametinib inhibits a target known as MEK and is effective primarily against melanomas carr
- Workshops Added to Aesthetic Extender Symposium 2013https://practicaldermatology.com/news/20130524-workshops_added_to_aesthetic_extender_symposium_2013/2459531/Five additional workshops will be held at the Aesthetic Extender Symposium (AES) at the Boca Raton Resort & Club from October 31 - November 3: Friday, November 1, 3:45 - 5:45 PM Innovations in Facial Aesthetic Medicine: Mastering the Art and Science of Injectables Michael Kane, MD & Jason Pozner,